Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Models of clinical infusional brachytherapy.

Order SE, Court WS.

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):279. No abstract available.

PMID:
11341241
2.

Preliminary experience of infusional brachytherapy using colloidal 32P.

Order SE, Siegel JA, Principato R, Zeiger LS, Johnson E, Lang P, Lustig R, Kroprowski C, Wallner PE.

Ann Acad Med Singapore. 1996 May;25(3):347-51.

PMID:
8876899
3.

Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice.

Zhang K, Loong SL, Connor S, Yu SW, Tan SY, Ng RT, Lee KM, Canham L, Chow PK.

Clin Cancer Res. 2005 Oct 15;11(20):7532-7.

4.

(32)P radioisotope therapy for recurrent pilocytic astrocytoma.

Narayana A, Bhatia S, Souweidane M, Khakoo Y, Zaider M.

Brachytherapy. 2005;4(2):171-3.

PMID:
15893272
5.

Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol.

Azab AK, Kleinstern J, Doviner V, Orkin B, Srebnik M, Nissan A, Rubinstein A.

J Control Release. 2007 Nov 6;123(2):116-22. Epub 2007 Aug 8.

PMID:
17854940
6.

Comment on "Design and bioevaluation of a ³²P-patch for brachytherapy of skin diseases" [Appl. Radiat. Isot. 66 (2008) 303-309].

Sahoo S, Palani Selvam T.

Appl Radiat Isot. 2014 Sep;91:62-3. doi: 10.1016/j.apradiso.2014.05.014. Epub 2014 May 27. No abstract available.

PMID:
24907684
7.

Development of samarium [32P] phosphate colloid for radiosynoviorthesis applications: preparation, biological and preliminary clinical studies experience.

Prabhakar G, Sachdev SS, Umamaheswari S, Sivaprasad N, Bhatia MH, Chaudhari PR, Solav SV.

Appl Radiat Isot. 2007 Dec;65(12):1309-13. Epub 2007 Jul 25.

PMID:
17764961
8.

Procedure for intraperitoneal P-32 administration.

Sharma SC.

Med Dosim. 1988;13(2):83-6.

PMID:
3251525
9.

Biological effects of brachytherapy using a (32)P-patch on the skin of Sencar mice.

Salgueiro MJ, Collia N, Durán H, Palmieri M, Medina V, Ughetti R, Nicolini J, Zubillaga M.

Appl Radiat Isot. 2009 Oct;67(10):1769-74. doi: 10.1016/j.apradiso.2009.05.006. Epub 2009 May 20.

PMID:
19525118
10.
11.
12.

Considerations on radiation source selection and utilization in vascular brachytherapy.

Crocker I.

J Invasive Cardiol. 2003 Nov;15(11):664-7; quiz 668.

PMID:
14608142
13.

Improving patient-specific dosimetry for intravascular brachytherapy.

Li XA, O'Neill M, Suntharalingam M.

Brachytherapy. 2005;4(4):291-7.

PMID:
16344260
14.

[Low-dose rate brachytherapy with locally integrated beta emitters after internal urethrotomy. A pilot project using an animal model].

Weidlich P, Adam C, Sroka R, Lanzl I, Assmann W, Stief C.

Urologe A. 2007 Sep;46(9):1231-5. German.

PMID:
17609925
15.

Late incomplete apposition with excessive remodeling of the stented coronary artery following intravascular brachytherapy.

Okura H, Lee DP, Lo S, Yeung AC, Honda Y, Waksman R, Kaluza GL, Ali NM, Bonneau HN, Yock PG, Raizner AE, Mintz GS, Fitzgerald PJ.

Am J Cardiol. 2003 Sep 1;92(5):587-90.

PMID:
12943881
16.

A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study.

Goh AS, Chung AY, Lo RH, Lau TN, Yu SW, Chng M, Satchithanantham S, Loong SL, Ng DC, Lim BC, Connor S, Chow PK.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):786-92. Epub 2006 Dec 4.

PMID:
17141975
17.

Bioevaluation of 32P patch designed for the treatment of skin diseases.

Salgueiro MJ, Duran H, Palmieri M, Pirchio R, Medina V, Ughetti R, Croci M, Nicolini J, Zubillaga M.

Nucl Med Biol. 2008 Feb;35(2):233-7. doi: 10.1016/j.nucmedbio.2007.08.004. Epub 2007 Nov 19.

PMID:
18312834
18.

32P brachytherapy in the treatment of complex Cypher in-stent restenosis.

Ortolani P, Marzocchi A, Aquilina M, Gaiba W, Neri S, Marrozzini C, Palmerini T, Taglieri N, Branzi A.

J Interv Cardiol. 2005 Jun;18(3):205-11.

PMID:
15966927
19.

Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.

Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.

Clin Cancer Res. 2005 Apr 15;11(8):3045-54.

20.

Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.

Fakiris AJ, Moore DH, Reddy SR, Look KY, Yiannoutsos CT, Randall ME, Cardenes HR; Hoosier Oncology Group.

Gynecol Oncol. 2005 Mar;96(3):818-23.

PMID:
15721431
Items per page

Supplemental Content

Write to the Help Desk